Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Eligibility Recurrent Pediatric ALL NCT00439296

- 2017-06-14 - 1 formulario, 3 itemgroups, 8 items, 1 idioma

Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria

ABT-751 With Chemotherapy for Relapsed Pediatric ALL; ODM derived from: https://clinicaltrials.gov/show/NCT00439296

SAE documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - SAE documentation AIEOP-BFM ALL 2009 NCT01117441

- 2021-03-15 - 1 formulario, 4 itemgroups, 39 items, 1 idioma

Itemgroups: Patient Information, Therapy, Severe adverse event, Identification and Signature

Study Description Stamm: International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation. Clinical Trial Number: NCT01117441.

Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-15 - 1 formulario, 4 itemgroups, 17 items, 1 idioma

Itemgroups: Patient Information, Laboratory Parameters Study Section, Laboratory Parameters Control Section, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Laboratory documentation. Clinical Trial Number: NCT01117441.

Laboratory Parameters R-HR AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Laboratory Parameters R-HR AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-15 - 1 formulario, 4 itemgroups, 17 items, 1 idioma

Itemgroups: Patient Information, Laboratory Parameters Study Section, Laboratory Parameters Control Section, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Laboratory documentation. Clinical Trial Number: NCT01117441.

HR-3 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-3 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-09 - 1 formulario, 4 itemgroups, 29 items, 1 idioma

Itemgroups: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

DNX-FLA regimen AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - DNX-FLA regimen AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-09 - 1 formulario, 3 itemgroups, 19 items, 1 idioma

Itemgroups: Patient Information, Chemotherapy Regimen, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

HR-2 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-2 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-09 - 1 formulario, 4 itemgroups, 39 items, 1 idioma

Itemgroups: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

HR-1 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-1 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-09 - 1 formulario, 4 itemgroups, 38 items, 1 idioma

Itemgroups: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

Documentation of therapy toxicity AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Documentation of therapy toxicity AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-31 - 1 formulario, 6 itemgroups, 25 items, 1 idioma

Itemgroups: Patient Information, Therapy, Blood analysis, Toxicity, Comments, Identification and Signature

Study Description Stamm: International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation of therapy toxicity. Clinical Trial Number: NCT01117441.

Maintenance therapy R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Maintenance therapy R2 AIEOP-BFM ALL 2009 NCT01117441

- 2021-03-15 - 1 formulario, 3 itemgroups, 21 items, 1 idioma

Itemgroups: Patient Information, Examinations, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

Protocol medication AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol medication AIEOP-BFM ALL 2009 NCT01117441

- 2016-07-14 - 1 formulario, 14 itemgroups, 57 items, 1 idioma

Itemgroups: Patient Information, First Element, Second Element, Third Element, Fourth Element, Fifth Element, Sixth Element, Seventh Element, Eighth Element, Ninth Element, Cranial radiation, Maintenance treatment, Comments, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation of administered protocol medication Clinical Trial Number: NCT01117441.

Initial survey AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Initial survey AIEOP-BFM ALL 2009 NCT01117441

- 2016-05-15 - 1 formulario, 9 itemgroups, 103 items, 1 idioma

Itemgroups: Patient Information, Anamnesis, Diagnosis, Blood analysis, Initial CNS status, Multi-organ involvement, Prednisone response, Comments, Identification and Signature

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Initial survey. Please send this document within one month after diagnosis to the study centre. Clinical Trial Number: NCT01117441.

Palabras clave

Tabla de contenido

Modelos de datos seleccionados

Eligibility Recurrent Pediatric ALL NCT00439296

SAE documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - SAE documentation AIEOP-BFM ALL 2009 NCT01117441

Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 NCT01117441

Laboratory Parameters R-HR AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Laboratory Parameters R-HR AIEOP-BFM ALL 2009 NCT01117441

HR-3 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-3 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

DNX-FLA regimen AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - DNX-FLA regimen AIEOP-BFM ALL 2009 NCT01117441

HR-2 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-2 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

HR-1 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-1 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

Documentation of therapy toxicity AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Documentation of therapy toxicity AIEOP-BFM ALL 2009 NCT01117441

Maintenance therapy R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Maintenance therapy R2 AIEOP-BFM ALL 2009 NCT01117441

Protocol medication AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol medication AIEOP-BFM ALL 2009 NCT01117441

Initial survey AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Initial survey AIEOP-BFM ALL 2009 NCT01117441

Palabras clave

Tabla de contenido

Modelos de datos seleccionados

Contacto

Ayuda